The Food & Drug Administration announced last week that the Ozempic and Wegovy shortage for Novo Nordisk‘s (NYSE:NVO) was ...
The LEAP Research and Innovation District, led by the Indiana Economic Development Corp., is among the costliest economic ...
We recently published a list of the 10 Oversold Pharma Stocks to Buy According to Analysts. In this article, we are going to take a look at where Novo Nordisk A/S (NYSE: NVO) stands against the other ...
Eli Lilly was second to the lucrative GLP-1 market for diabetes and obesity following its chief metabolic medicine rival Novo ...
President Trump also refused to promise pharma execs that he would hamstring the IRA’s drug negotiation program.
Revenues in the biopharma industry continued to boom in the fourth quarter of last year, following a pattern seen increasingly throughout 2024. | Revenues in the biopharma industry continued to boom ...
Eli Lilly kicks off 2025 with key licensing deals and M&A, boosting its position across therapeutic areas amid rising drug ...
A global manufacturer acquired a Shawnee facility in the fall, the third time it and its 300 employees have changed hands ...
Eli Lilly is making a bold move with its experimental weight-loss pill, orforglipron, by recording nearly $550 million in ...
President Donald Trump reportedly issued a stringent warning to pharmaceutical companies, advising them to repatriate their ...
We recently published a list of Top 10 Stocks to Buy According to Sustainable Insight Capital Management. In this article, we ...
Eli Lilly's stock offers high growth potential, driven by GLP-1 therapies and strong R&D efforts. Read why LLY stock is ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results